View Older Stories
-
Tonix Pharma (TNXP) Reports In-Line Q3 EPS
-
Tonix presents fibromyalgia drug data at rheumatology conference
-
Tonix presents mpox vaccine data at European conference
-
Tonix presents TNX-1500 data at Japan transplantation congress
-
Tonix Pharmaceuticals names Ganesh Kamath head of market access
-
Tonix receives FDA feedback for depression drug development
-
Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
-
Tonix Pharma (TNXP) gains after market on Tonmya approval
-
Tonix Pharma (TNXP) halted, news pending
-
Tonix Pharma (TNXP) Falls as Much as 75%, Pares Decline to Down 17% Amid Jitters Ahead of FDA Decision
-
Tonix Pharma (TNXP) Tops Q2 EPS by 297c
-
Tonix presents data on mpox and smallpox vaccine candidate at Vienna congress
-
Tonix publishes phase 3 fibromyalgia trial results in Pain Medicine
-
Tonix to present mpox vaccine data at Vienna congress
-
Tonix Pharma (TNXP) Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models
-
Tonix Pharma (TNXP) Files $500M Mixed Shelf
-
Tonix Pharma (TNXP) Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction
-
Tonix Pharma (TNXP) Tops Q1 EPS by 284c
-
Tonix Pharma (TNXP) Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025
-
Tonix Pharma (TNXP) and Makana Therapeutics Announce Collaboration Combining TNX-1500 with Makana’s Genetically Engineered Organs
-
Tonix Pharma (TNXP) Launches TONIX ONE
-
Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year
-
New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc.
-
Noble Capital Out Positive on Tonix Pharma (TNXP) Following FDA Update, 'We continue to expect product approval on or before August 15, 2025'
-
Tonix Pharma (TNXP) Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL
-
As Mpox Cases Spread Around the World, Tonix Pharmaceuticals’ Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread
-
Tonix Pharma (TNXP) Misses Q4 EPS by 586c
-
Tonix’s TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target
-
Tonix Pharma (TNXP) Reports Prelim FY24 Results
-
Tonix Pharma (TNXP) Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoim
-
Tonix Pharma (TNXP) Appoints Siobhan Fogarty as CTO
-
Tonix Pharma (TNXP) Announces 1:100 Reverse Share Split
-
Tonix Pharma (TNXP) Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102
-
Tonix Pharma (TNXP) Announces FDA Acceptance of the NDA for TNX-102
-
Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers
-
Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments
-
Tonix Pharma (TNXP) Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company’s Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised A
-
Tonix Pharma (TNXP) Tops Q3 EPS by 270c
-
Tonix Pharma (TNXP) Presented Data on Potential Mpox Vaccine TNX-801
-
Tonix Pharma (TNXP) Receives First Contract Payment from U.S. DoD for Accelerated Development of Broad-Spectrum Antivirals with the DTRA
-
Tonix Pharma (TNXP) Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration
-
Tonix Pharma (TNXP) Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals
-
The Rush for Non-Addictive Painkillers to Counter the Opioid Crisis Puts Two Companies Close to FDA Decisions
-
Tonix Pharma (TNXP) Issued US Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch to Treat Migraines
-
Tonix Pharma (TNXP) Announces Data Presentations on TNX-102 SL for Fibromyalgia at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems
-
Tonix Pharma (TNXP) Announces Issuance of U.S. Patent Covering the Intranasal Delivery of FDA-Approved Tosymra to Treat Migraines
-
New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution
-
Tonix Pharma (TNXP) Announces TNX-801 Aligns with WHO’s Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency
-
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
-
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

